SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Ciesielski, PhD
Chief Executive Officer
Study Director - Robert Fenstermaker, MD
Chief Medical Officer
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California
San Francisco, California, United States
- Miami Cancer Institute
Miami, Florida, United States
- Norton Cancer Center
Louisville, Kentucky, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Atlantic Health
Summit, New Jersey, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Nyu Langone Health
New York, New York, United States
- Northwell
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Texas Oncology
Austin, Texas, United States
- Fred Hutchinson Cancer Center (fhcc)
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Nov 2021
- Primary completion
- 18 Aug 2024
- Completion
- 18 Aug 2024
- Last update posted
- 26 Feb 2024
- Registered enrollment
- 247
- Registry id
- NCT05163080
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.